VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide (2018)
Sequence: RAGLPFQVGRLLRRLLR
| Experiment Id | EXP000925 |
|---|---|
| Paper | VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide |
| Peptide | BR2 (cancer-specific CPP) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | complexed with 200 pmol siRNA at N/P=8 (1 h transfection) |
| Rna Concentration | 200 pmol per well (12-well; 1 mL; 1 h exposure) |
| Mixing Ratio | N/P = 8 |
| Formulation Format | noncovalent CPP-siRNA complexes (electrostatic; N/P ratio) |
| Formulation Components | BR2 peptide + siVEGF |
| Size Nm | 200.00 |
| Zeta Mv | 8.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa and HCT116 (VEGF silencing); HeLa/HCT116/HaCat/NIH3T3 (uptake & toxicity) |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro knockdown (VEGF ELISA + qRT-PCR); uptake (FACS FITC-siVEGF) |
| Output Value | HeLa: VEGF secretion down 60.1% and VEGF mRNA down 43.2% |
| Output Units | |
| Output Notes | Gel retardation shows full complexation at N/P>=4; serum stability in 50% FBS (4 h) at N/P>=4. Uptake by FACS after 1 h transfection with FITC-siVEGF at N/P=8; higher uptake in cancer vs non-cancer lines. |
| Toxicity Notes | MTT (24 h): viability >90% across cell lines; HeLa ~80% at higher BR2 dose (N/P up to 32). |
| Curation Notes |